| Autor: |
Zvorsky I; Charlotte's Web., Kulpa J, Mechtler LL; Dent Neurologic Institute., Ralyea CC; Dent Neurologic Institute., Lombardo J; Center for Integrated Global Biomedical Sciences, University of Buffalo., Del Re AC; Del Re Data and Statistical Consulting., Bonn-Miller MO; Charlotte's Web. |
| Jazyk: |
angličtina |
| Zdroj: |
Experimental and clinical psychopharmacology [Exp Clin Psychopharmacol] 2024 Nov 07. Date of Electronic Publication: 2024 Nov 07. |
| DOI: |
10.1037/pha0000747 |
| Abstrakt: |
A growing number of hemp-derived cannabidiol (CBD) products are available with negligible amounts (< 100 ppm) of delta-9-tetrahydrocannabinol (THC) due in part to consumer concerns regarding the risk of positive drug screens. There are, however, no published studies that report whether repeated use of these products may lead to positive urine drug tests for THC. There is also scant research on the effects of these products on physical and mental well-being. Twenty healthy adults consumed a hemp-derived broad-spectrum CBD product every day for 2 weeks. Participants attended study visits at the beginning and end of the 2-week period. At each visit, participants underwent urinalysis testing for CBD, THC, and metabolites (analyzed via liquid chromatography with tandem mass spectrometry) and completed a validated assessment of physical and mental well-being. Participants reported using an average of 1.09 ± 0.51 ml (34.20 ± 16.00 mg CBD) of study product per day. Neither tetrahydrocannabinol nor its metabolites were detectable in urine following the 2-week period of use. Ingestion of the broad-spectrum product was associated with a significant reduction in sleep disturbance and pain intensity symptoms ( p < .05), which remained significant after correcting for possible confounds (i.e., age, sex, dosage). No adverse events were reported. (PsycInfo Database Record (c) 2024 APA, all rights reserved). |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
